Literature DB >> 20053337

Institution affects association between CMV seronegative graft and leukemic relapse after pediatric HCT.

Carolyn E Behrendt, Ryotaro Nakamura, John Zaia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20053337      PMCID： PMC2811877          DOI： 10.1016/j.bbmt.2009.06.010

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  9 in total

1.  Human cytomegalovirus infection induces a rapid and sustained change in the expression of NK cell receptors on CD8+ T cells.

Authors:  Amber van Stijn; Ajda T Rowshani; Sila L Yong; Frank Baas; Eddy Roosnek; Ineke J M ten Berge; René A W van Lier
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

2.  Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture.

Authors:  M Boeckh; G M Gallez-Hawkins; D Myerson; J A Zaia; R A Bowden
Journal:  Transplantation       Date:  1997-07-15       Impact factor: 4.939

3.  Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus.

Authors:  Andrea Sáez-Borderías; Mónica Gumá; Ana Angulo; Beatriz Bellosillo; Daniela Pende; Miguel López-Botet
Journal:  Eur J Immunol       Date:  2006-12       Impact factor: 5.532

4.  Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts.

Authors:  Mónica Gumá; Matthias Budt; Andrea Sáez; Tamara Brckalo; Hartmut Hengel; Ana Angulo; Miguel López-Botet
Journal:  Blood       Date:  2005-12-29       Impact factor: 22.113

5.  Donor CMV serostatus not predictive of relapse in D-/R- pediatric HCT.

Authors:  Giovanna Travi; Steven A Pergam; Hu Xie; Michael J Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-06       Impact factor: 5.742

6.  Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy.

Authors:  Carolyn E Behrendt; Joseph Rosenthal; Ellen Bolotin; Ryotaro Nakamura; John Zaia; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

7.  Imprint of human cytomegalovirus infection on the NK cell receptor repertoire.

Authors:  Mónica Gumá; Ana Angulo; Carlos Vilches; Natalia Gómez-Lozano; Núria Malats; Miguel López-Botet
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

8.  Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.

Authors:  C R Li; P D Greenberg; M J Gilbert; J M Goodrich; S R Riddell
Journal:  Blood       Date:  1994-04-01       Impact factor: 22.113

9.  Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis.

Authors:  Minoo Battiwalla; Yiyuan Wu; Rajinder P S Bajwa; Marija Radovic; Nikolaos G Almyroudis; Brahm H Segal; Paul K Wallace; Ryotaro Nakamura; Swaminathan Padmanabhan; Theresa Hahn; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2007-05-07       Impact factor: 5.742
  9 in total
  2 in total

1.  Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant.

Authors:  Jonathan U Peled; Robert R Jenq
Journal:  Leuk Lymphoma       Date:  2016-10-12

2.  Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission.

Authors:  Jae-Ho Yoon; Seok Lee; Hee-Je Kim; Young-Woo Jeon; Sung-Eun Lee; Byung-Sik Cho; Dong-Gun Lee; Ki-Seong Eom; Yoo-Jin Kim; Chang-Ki Min; Seok-Goo Cho; Woo-Sung Min; Jong Wook Lee
Journal:  Oncotarget       Date:  2016-03-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.